Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce cardiovascular events in people with type 2 diabetes mellitus and high cardiovascular risk [11–15]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.